Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT00930553) enrolled 1,314 people with multiple sclerosis (MS) who had previously taken part in one of three earlier studies. All participants received the drug alemtuzumab during this extension phase. The trial was measuring how often participants experienced MS relapses (sudden worsening of symptoms) over time, and whether their level of disability — scored on a standard scale — changed. Of the 1,314 who started, 1,091 completed the study and 223 did not. The reported data shows that for participants who had been on alemtuzumab throughout, the average number of relapses per person per year (called the annualised relapse rate) ranged from approximately 0.12 to 0.24 across different follow-up periods and participant groups. For people who had previously been on a different MS medicine (interferon beta-1a) and then switched to alemtuzumab, the reported relapse rate before switching was 0.42 and 0.60 (depending on which earlier study they came from), and after switching it was reported as 0.14 and 0.15 respectively. For people who received an additional course of alemtuzumab, the reported relapse rate before that extra course was 0.79, and afterwards ranged from 0.18 to 0.30 across different measurement windows. On the disability scale (which runs from 0 to 10, with higher numbers meaning greater disability), the reported data shows that 79 and 118 participants (from the two main groups) experienced a confirmed worsening in disability that lasted at least six months. The reported data also shows that 74 and 130 participants (from the same two groups respectively) experienced a sustained improvement of at least one point on the disability scale lasting six months or more. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Multiple Sclerosis Trial, Completed
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You took part in a previous related study called CAMMS323 or CAMMS324, received the drug alemtuzumab, completed the full 2-year study, and did not go on to take other MS treatments afterward (except glatiramer acetate or interferon beta)
- You took part in CAMMS323 or CAMMS324, received the drug Rebif®, completed the full 2-year study, and did not go on to take other MS treatments afterward (except glatiramer acetate or another interferon beta medication)
- You took part in an earlier related study called CAMMS223
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You previously received alemtuzumab outside of the official Genzyme-sponsored studies mentioned above
- You are currently taking part in another research study (unless the trial organizers, Genzyme, have given special approval)
- You do not wish to receive the drug alemtuzumab as part of this trial
- You have a bleeding disorder or are taking blood-thinning medication
- You have been diagnosed with a blood-related autoimmune condition, such as idiopathic thrombocytopenia purpura
- You have a history of cancer (except a common, treatable form of skin cancer called basal cell carcinoma)
- You have had serious reactions to steroid treatments in the past, such as steroid-related psychiatric episodes
- You have a significant autoimmune disease other than MS
- You have a major psychiatric condition or epileptic seizures that are not well controlled with treatment
- You currently have an active infection or are considered at high risk of getting one
- You are able to have children and are unwilling to use a reliable form of contraception during treatment and for at least 6 months after each treatment cycle
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, including 11 in Australia. They are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Annualized Relapse Rate (ARR); Annualized Relapse Rate (ARR) Before and After Receiving Alemtuzumab; Annualized Relapse Rate (ARR) Before and After Alemtuzumab Retreatment; Number of Participants With Sustained Accumulation of Disability (SAD); Number of Participants With Sustained Accumulation of Disability (SAD) Before and After Alemtuzumab Treatment: 2 Year Comparison
Other options
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.